Annovis Bio, Inc. (ANVS)
- Previous Close
9.13 - Open
9.13 - Bid 8.80 x 1200
- Ask 9.50 x 1100
- Day's Range
8.62 - 9.15 - 52 Week Range
4.53 - 22.49 - Volume
208,140 - Avg. Volume
1,775,814 - Market Cap (intraday)
119.183M - Beta (5Y Monthly) 1.74
- PE Ratio (TTM)
-- - EPS (TTM)
-4.54 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.40
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
www.annovisbio.comRecent News: ANVS
View MorePerformance Overview: ANVS
Trailing total returns as of 8/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANVS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANVS
View MoreValuation Measures
Market Cap
119.18M
Enterprise Value
115.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
19.68
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-183.39%
Return on Equity (ttm)
-453.01%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-43.02M
Diluted EPS (ttm)
-4.54
Balance Sheet and Cash Flow
Total Cash (mrq)
4M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-14.05M